



An Independent Licensee of the Blue Cross and Blue Shield Association

Guideline for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease

2025

Adopted by CHP Quality Improvement Committee:

9/8/09, 5/10/11, 5/14/13, 5/12/2015, 5/9/2017, 5/14/2019, 3/9/2021, 7/11/2023, 11/11/2025

Secondary Prevention of Cardiovascular Disease

2025 Summary

I. Introduction

Patients with established atherosclerotic cardiovascular disease (ASCVD) have a high risk of subsequent ASCVD events, including myocardial infarction (MI), stroke, and death.

Therapeutic lifestyle changes in the form of increased physical activity, dietary modification/weight loss, and smoking cessation improves outcomes, some beginning within a matter of weeks. In addition, adjunctive drug therapies of proven benefit include aspirin and statins, whose benefits are at least additive. Additional measures include treatment of dyslipidemia and hypertension and management of diabetes mellitus.

This guideline is an overview of prevention of ASCVD events in those with established ASCVD. This includes individuals with:

- A. History of a cardiovascular event such as MI, stroke, or transient ischemic attack
- B. Symptomatic presentations of ASCVD such as angina or limb claudication
- C. Unequivocal imaging evidence of ASCVD such as CT coronary angiogram

II. Dyslipidemia

- A. Management of dyslipidemia, particularly reduction of low-density lipoprotein (LDL) cholesterol, is essential in individuals with atherosclerotic cardiovascular disease.
- B. We treat virtually all patients with atherosclerotic cardiovascular disease (CVD) with evidence-based doses of a high-potency statin and add nonstatin agents, such as ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors, for LDL management when indicated.

III. Hypertension

- A. Therapies: See Adjunctive Therapies (below)
 - Lifestyle: We recommend therapeutic lifestyle changes for all apparently healthy individuals. In addition, this recommendation should be especially emphasized to patients with blood pressures of 120/80 mmHg or greater. The institution of therapeutic lifestyle changes of proven benefit poses little or no risks and are all likely to be beneficial for all patients regardless of blood pressure. Therapeutic lifestyle changes of proven benefit include:
 - Weight loss

- Increased physical activity
- Dietary sodium restriction
- Reduction or avoidance of alcohol

IV. Diabetes Mellitus

A. Apart from their role in glycemic control, some antidiabetic agents provide additional cardiovascular benefits in patients with diabetes and atherosclerotic cardiovascular disease:

- Selected sodium-glucose cotransporter 2 inhibitors
- Glucagon-like peptide 1 receptor agonist agents

V. Lifestyle Modifications

Lifestyle modifications have important beneficial effects on CVD morbidity and mortality that begin relatively shortly after their institution.

A. Diet:

- In observational studies, individuals who self-select for healthy diets experience significantly lower CVD event rates. Dietary interventions, in particular a Mediterranean diet, improve outcomes in patient with established CVD.
- We encourage adherence to diets that emphasize high intakes of vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish.
- Diets should minimize the intake of trans fats, red meat, and processed red meats, refined carbohydrates, and sweetened beverages.
- The European Society of Cardiology (ESC) guidelines on CVD prevention (both primary and secondary) make a recommendation for a Mediterranean or similar diet to reduce CVD risk. Further, they suggest replacing saturated with unsaturated fats, reducing salt intake, choosing a plant-based food pattern high in fiber, and eating fish, preferably fatty, at least once a week.
- For patients with known CVD or those at high risk who consume fish or are willing to do so, we recommend that they consume at least one to two servings per week of oily fish, which is consistent with the AHA recommendations.

B. Weight Reduction:

- In large-scale prospective studies, individuals who are overweight or obese have increased risks for CVD across a large range of levels. In the United States as well as other resource-rich countries, overweight and obesity may be overtaking smoking as the leading avoidable cause of premature death. Weight reduction is difficult to achieve and maintain; among the 90% of subjects who are successful initially, about 90% of those eventually regain the lost weight. However, a clear benefit of weight reduction on cardiovascular outcomes has not been clearly demonstrated.
- Overweight and obesity are also major contributors to metabolic syndrome, a constellation of hypertension, dyslipidemia, and insulin resistance, leading to diabetes. In the United States, metabolic syndrome, which confers high risk of a first CVD event, occurs in about 40% of individuals over age 40. In addition, overweight and obesity in the absence of metabolic syndrome also confer significantly increased risks of CVD.
- All patients with CVD should have a measurement of waist circumference and a calculation of body mass index. Weight reduction is optimally achieved with multiple strategies, including diet, increased physical activity, and possible pharmacologic therapy.

C. Physical Activity:

- Regular physical activity has numerous cardiovascular benefits, including weight loss, improvement in lipid profile, and reductions in blood pressure, as well as prevention and management of type 2 diabetes. All these beneficial effects lead to improvement in CVD morbidity and mortality.
- Prior to initiation of an activity program, most high-risk patients should undergo risk assessment with a physical activity history and/or an exercise test.
- We agree that the following recommendation for physical activity made in the 2019 ACC/AHA guideline on primary prevention of CVD is applicable to secondary prevention: Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per week of vigorous-intensity physical activity.

D. Smoking Cessation:

- Smoking cessation is associated with significant reductions in cardiovascular outcomes. The elevated CVD risk associated with smoking begins to decline within months of smoking cessation and declines to that of individuals who have never smoked within three to five years. These benefits have been shown in secondary and primary prevention.

- In a meta-analysis of observational studies that included 12,603 participants who smoked and had a prior myocardial infarction, coronary artery bypass graft surgery, angioplasty, or known coronary heart disease, quitting smoking was associated with a reduced mortality risk compared with continuing to smoke (relative risk 0.64, 95% CI 0.58-0.71)
- In a cohort study of 2619 patients, longer durations of smoking cessation after an incident MI were associated with progressively decreasing risks of recurrent coronary events (RR 1.62 [0 to <6 months], 1.60 [6 to <18 months], 1.48 [18 to <36 months, and 1.02 [\geq 36 months]).
- Passive smoking has been clearly linked with a higher risk of CVD. Banning smoking in public places quickly reduced the incidence of acute MI in many observational studies.

E. Alcohol:

- Heavy alcohol consumption and binge drinking increase the risk for CHD. The effects of low to moderate alcohol intake are less clear.

F. Cardiac Rehabilitation Program:

- We recommend referral to a comprehensive, outpatient cardiovascular rehabilitation program for all eligible patients with a recent acute coronary syndrome (ACS) or revascularization procedure. Other patients, such as those with these diagnoses in the past year, those with chronic angina, or those with peripheral artery disease, may be candidates for referral. These programs are usually designed to provide the patient with assistance in lifestyle modification.

G. Text Messaging:

- Not all patients are able to attend a cardiac rehabilitation program, and many programs limit the number of sessions. Another way to deliver assistance to patients in the adoption of a healthy lifestyle may be for the patient to receive mobile phone text messages periodically. The TEXT ME study randomly assigned 710 patients with CHD to a text message-based prevention program that delivered semi-personalized text messages four times per week with advice, motivation, and information to improve diet, increase physical activity, and encourage smoking cessation (if applicable). At six months, the intervention group had statistically significant improvement in LDL cholesterol (79 vs 84 mg/dL), systolic blood pressure (128.2 versus 135.8 mmHg), BMI (29.0 versus 30.3), physical activity (936 versus 642.7 metabolic equivalent minutes/week), and percent of patients who smoked (26.0 versus 42.9).

VI. Adjunctive Therapies

All patients with established cardiovascular disease (CVD) and many other high-risk patients should receive aspirin and statin therapy. Other medications that may be of benefit in some patients include beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Aldosterone blockers, platelet P2Y₁₂ receptor blockers, colchicine, and oral anticoagulants. Administration of influenza vaccine also appears to be beneficial in patients with CV.

A. Antiplatelet therapy:

- For patients with established CVD, we recommend long-term aspirin therapy. Long term antiplatelet therapy with aspirin reduces the risk of subsequent myocardial infarction (MI), stroke, and cardiovascular death among patients with a wide range of manifestation of occlusive CVD. In patients who are unable to take aspirin and in those with a history of gastrointestinal bleeding, clopidogrel is a reasonable alternative.
- For patients who have undergone percutaneous coronary intervention (PCI) with stenting or those who have an acute coronary syndrome (ACS), a P2Y₁₂ receptor blocker is added to aspirin for some period of time.
- Individuals with stable coronary artery disease (CAD) and diabetes who are at very high ischemic risk may benefit from dual antiplatelet therapy (DAPT), especially if their baseline risk of bleeding is low. DAPT typically consists of aspirin with either ticagrelor or clopidogrel. Because reduction in coronary events may be offset by increases in the risk of major bleeding, clinicians should individualize risk assessment and discuss both the benefits of preventing recurrent CVD events and the risks of bleeding with DAPT.
- In the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (Themis) of 19,220 adults with chronic coronary syndrome and type 2 diabetes mellitus, patients randomized to ticagrelor 60 mg twice daily and low-dose aspirin experienced lower rates of ischemic CVD events (cardiovascular death, MI, or stroke) at 40 months, compared with those randomized to low-dose aspirin alone (7.7 versus 8.5 percent; hazard ratio [HR] 0.90; 95% CI 0.81-0.99). However, those randomized to ticagrelor plus aspirin also had increased rates of major bleeding (2.2 versus 1.0 percent; HR 2.32; 95% CI 1.82-2.94) and intracranial hemorrhage (0.7 versus 0.5 percent; HR 1.71; 95% CI 1.18-2.48). Based on these data, the US Food and Drug Administration approved DAPT for those with chronic coronary syndrome (with or

without diabetes).

- In a prespecified subgroup analysis of the 11,154 participants with PCI, ticagrelor and aspirin decreased rates of ischemic CVD events, compared with aspirin alone (7.7 versus 8.6 percent; HR 0.85; 95% CI 0.74-0.97). They also had higher rates of major bleeding (2.0 versus 1.1 percent) but comparable rates of intracranial hemorrhage, fatal bleeding, cardiovascular mortality, and all cause mortality.

B. Anticoagulant Therapy:

- In patients who require full-dose anticoagulation for a specific indication, such as atrial fibrillation or venous thromboembolic disease, we typically do not add aspirin, since this increases the risk of bleeding.
- In patients without a specific indication for anticoagulation, we do not substitute or add full-dose oral anticoagulant therapy to aspirin therapy to lower the risk of subsequent CVD events. For select patient with stable CAD on antiplatelet therapy who are at high risk of cardiovascular events and low risk of bleeding, adding rivaroxaban 2.5 mg orally twice daily may be considered, based on results of the Cardiovascular Outcomes for People using Anticoagulation Strategies (COMPASS) trial. Such patients include those with peripheral artery disease or a history of ischemic stroke, multivessel CAD, incomplete coronary revascularization, diabetes, patients with body weight >60 kg (132 pounds), prior coronary artery bypass surgery, chronic kidney disease, or multiple prior ischemic events.
- A large, randomized trial has evaluated the efficacy of adding low-dose rivaroxaban, and oral direct Xa inhibitor, to aspirin therapy for secondary CVD prevention in individuals at high risk of CVD events. In the COMMPASS trial, 27,395 patients with stable CAD or peripheral arterial disease were randomly assigned to rivaroxaban plus aspirin, rivaroxaban alone, or aspirin alone with a mean follow-up of 23 months. The dose of rivaroxaban in the combination arm was 2.5 mg orally twice per day; in the rivaroxaban-only arm, the dose was 5 mg orally twice per day. Compared with those assigned at random aspirin alone, patients assigned to rivaroxaban plus aspirin had a 22 percent significant decrease in cardiovascular mortality (1.7 versus 1.4 percent; HR 0.78, 95% CI 0.64-0.96) and 49 percent decrease in ischemic stroke (0.7 versus 1.4 percent; HR 0.51, 95% CI 0.38-0.68). There was also a possible but nonsignificant 14 percent reduction in MI (1.9 percent; HR 1.70, 95% CI 1.40-2.05), with the gastrointestinal tract being the most common site of major bleeding. The risk of intracranial hemorrhage was comparable between the two groups. Mortality and cardiovascular outcomes were similar in the

rivaroxaban-alone and aspirin-alone groups, but there were significantly more major bleeding events in those assigned to rivaroxaban and aspirin. Clinicians should be aware of the balance between prevention of thrombosis and causing serious bleeding.

C. Beta Blockers:

- In patients with recent acute MI or in those with heart failure (HF) due to systolic dysfunction, oral beta blockers may be a part of their treatment regimen.
- In patients with chronic coronary syndrome and angina, beta blockers reduce the severity of frequency of anginal attacks. With the exception of patients with HF, the evidence is limited about whether beta blockers lower the risk of death in patients with chronic coronary syndrome when combined with contemporary secondary prevention strategies.

D. ACE inhibitors or ARBs:

- Many patients with established CVD will benefit from ACE inhibitor or ARB therapy. The most common indications are the attainment of goal blood pressure, the treatment of acute MI, or the presence of HF, left ventricular ejection fraction below 40 percent, diabetes, or proteinuric kidney disease.
- Other high-risk individuals include those with diabetes or chronic kidney disease. In these high-risk patients, ACE inhibitors and ARBs have been hypothesized to have cardio-protective effects independent of blood pressure lowering, but the available evidence suggest that the attained blood pressure is of primary importance. ACE inhibitors or ARBs may also be a first-line drug of choice to control blood pressure in diabetic and metabolic syndrome patients with or without prior MI.

E. Polypill:

- Polypills combine fixed doses of medication such as aspirin, ace-inhibitor and statin into one pill and have been proposed as a method to increase medication adherence.
- In the Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) trial of nearly 2500 patients from 7 European countries with recent MI, treatment with a Polypill containing aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg) was shown to lower risk of major adverse cardiovascular events compared with usual care. Eligible patients were either older than 75 or at least 65 years of age with at least one additional risk factor (diabetes mellitus, mild or moderate kidney

disease, previous MI [defined as infarction occurring before the index event], previous coronary revascularization). The mean age of participants was 76 years and 70 percent were male. Time from MI to randomization was a median of 8 days (interquartile range 3 to 37).

- After 36 months of follow-up, the following outcomes were observed:
 - Those assigned to the Polypill events had had lower rates of cardiovascular events (cardiovascular death, nonfatal type 1 myocardial infarction, nonfatal ischemic stroke, or urgent revascularization): 9.5 vs 12.7 percent; hazard ratio [HR] 0.76, 95% CI 0.60-0.96) compared with the usual care group.
 - There were no difference in blood pressure or LDL cholesterol levels during follow-up between the two treatment groups.
 - Medication adherence as reported by the patients was higher in the Polypill versus usual care group.
 - Adverse event rates were similar between treatment groups.
 - A lack of difference in follow-up blood pressure or LDL cholesterol suggest that the ramipril and statin components of the Polypill had pleiotropic effects, beyond the lowering of these risk factors, that resulted in lower rates of secondary CVD.

F. Mineralocorticoid Receptor Antagonist:

- The use of a mineralocorticoid receptor antagonist (e.g. Spironolactone or eplerenone) is recommended for certain patients with heart failure and reduced ejection fraction.

G. Colchicine:

1. For patients with chronic CAD receiving other secondary preventive drug therapies (which may include statins and/or other antiplatelet agents), we suggest adding colchicine 0.5 (or 0.6) mg per day. In randomized trials in the secondary prevention of CAD, colchicine improved cardiovascular outcomes. Although studies have evaluated colchicine doses that range from 0.5 to 1 mg daily, we typically use 0.6 mg daily because it is available in the United States as a generic formulation and less expensive.
2. The most common side effects (diarrhea, nausea, vomiting, and abdominal pain) are usually mild. Transient, and usually painless, elevations of creatinine kinase have also been reported; this may be related to other drugs such as statins or other lipid-lowering drugs. This dosage of colchicine may be reduced in patients taking P-glycoprotein (P-gp) inhibitors or strong CYP3A4 inhibitors, including certain beta

blockers, calcium channel blockers, or amiodarone. Colchicine is contraindicated in patients with renal or hepatic impairment.

3. Colchicine reduced risks of cardiovascular events in the Low-Dose Colchicine 2 (LoDoCo2) trial. This trial randomly assigned 5522 patients, 85 percent men, with chronic CAD to 0.5 mg of colchicine once per day or placebo. Almost all trial participants were taking lipid-lowering agent and a antithrombotic therapy (i.e., antiplatelet or anticoagulant). After two and a half years, those assigned to colchicine had a decreased risk of the primary composite endpoint (HR 0.69, 95% CO 0.57-0.83), with reductions in MI (3.0 versus 4.2 percent; HR 0.70, 95% CI 0.53-0.93) and ischemia-driven coronary artery revascularization (4.9 versus 6.4 percent; HR 0.75, 95% CI).60-0.94). The incidence of death from non-cardiovascular causes appeared higher in the colchicine group; however, this finding did not achieve statistical significance (0.7 versus 0.5 percent; HR 1.51, 95% CI 0.99-2.31). All-cause mortality was similar in both groups (RR 1.08, 95% CI0.71-1.62). Colchicine produced no significant adverse effects except for a somewhat higher rate of myalgia (21.2 versus 18.5 percent). In post hoc subgroup analyses, benefits were similar among those with and without a history of prior ACS or timing of reported ACS. A subsequent meta-analysis had similar findings to those of LoDoCo2.

H. Sodium-glucose cotransporter 2 inhibitors

1. Certain sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular outcomes in patients with heart failure with reduced ejection fraction (with and without diabetes mellitus) and in patients with type 2 diabetes mellitus and existing CVD.

I. Glucagon-like peptide 1 receptor agonists

- Selected glucagon-like peptide 1 receptor agonists reduce cardiovascular outcomes in individuals with established ASCVD or at high risk of ASCVD.

J. Marine Omega-3 Fatty Acids:

1. Many patients with established CVD or at high risk of CVD have hypertriglyceridemia. We do not routinely recommend marine omega-3 fatty acids in individuals with CAD without hypertriglyceridemia. For such patients, there is less evidence supporting their use.

K. COVID-19 and Influenza Vaccinations:

1. We encourage all patients with CVD to receive periodic vaccination against COVID-19, which continues to mutate and confers high risk of hospitalizations and deaths.

2. As with adults in the general population, we recommend annual influenza vaccine for patient with CVD.
3. Individuals with established CVD and high-risk primary prevention subjects have increased risks for complications of influenza infection. In a cross-sectional study of 80,000 adults hospitalized with influenza (of who 20 percent had chronic CVD, 20 percent chronic kidney disease, and 15 percent diabetes), 11.7 percent had an acute cardiovascular event during hospitalization, most commonly acute HF or acute ischemic heart disease.
4. Influenza vaccines may reduce mortality and CVD outcomes in these patients. In a 2013 meta-analysis of trials conducted among persons with CVD or at high risk, those receiving an influenza vaccine had fewer cardiovascular events than those in the control group. A randomized clinical trial of 2571 participants at 30 centers across eight countries found that primary outcomes (all-cause death, MI, and stent thrombosis) were less frequent in participants assigned influenza vaccine versus those assigned placebo (5.3 versus 7.2 percent)

L. Therapies with uncertain or no benefit:

A. Antioxidant vitamins:

1. Antioxidant vitamins, which are nonprescription and sold over the counter, have promising basic research and supportive observational data, but the randomized evidence has not demonstrated clinical benefits on CVD in secondary or primary prevention. The hypotheses that vitamin E, Beta carotene, and/or vitamin C decrease the risks of CVD has been tested in several large-scale randomized trials in secondary and primary prevention. The results have not supported either the potential beneficial mechanisms suggested from basic research or possible benefits hypothesized from observational studies.

B. Homocysteine and Folic Acid:

1. Although, in observational studies, subjects with elevated levels of homocysteine have an increased risk of CHD and, given the fact that vitamin supplementation with folic acid lowers homocysteine levels, data from multiple randomized trial designed to test the hypothesis show no significant benefits to folic acid supplementation of the risks of CVD

C. Postmenopausal Hormone Therapy

D. Chelation:

1. The totality of evidence does not support a recommendation for chelation therapy in patients with CAD. As an example, in the 2024 Trial to Assess Chelation therapy 2 (TACT2) of 959 participants with diabetes and prior myocardial infarction, ethylenediaminetetraacetic acid-based chelation reduced blood lead levels but was not superior to placebo in reducing the composite endpoint of death, recurrent MI, stroke, coronary revascularization, or hospitalization for angina (35.6 versus 35.7 percent; hazard ratio [HR] 0.93; 95% CI 0.76-1.16) or any of the individual components endpoints.

E. Cholesteryl-ester Transfer Protein Inhibitors:

1. Inhibition of the cholesteryl-ester transfer protein (CETP) leads to large increases in high-density lipoprotein (HDL) and modest reductions in low-density lipoprotein (LDL). Of four large trials, three were terminated early, two for lack of benefit and one due to clear evidence of harm. In the fourth trial, the addition of the CETP inhibitor anacetrapib to intensive statin treatment in patients with atherosclerotic vascular disease resulted in a modest but significantly lower incidence of major coronary events than the addition of placebo.

F. Methotrexate:

1. Methotrexate has been postulated to lower the risk of CVD by reducing inflammation. However, in the Cardiovascular Inflammation Reduction Trial (CIRT) of 4786 patients with known MI or multi-vessel CAD who also had diabetes mellitus or metabolic syndrome, rates of the combined CDVD outcome (nonfatal MI, nonfatal stroke, or cardiovascular death) were similar between the low-dose methotrexate (15 to 20 mg weekly) and placebo groups.

G. Allopurinol:

1. Among patients with gout, observational studies suggest that urate-lowering therapy with allopurinol is associated with lower CVD and mortality. However, larger trial of allopurinol in patients with ischemic heart disease and no history of gout did not show that it was efficacious in reducing rates of cardiovascular disease. In the ALL-HEART open-label multicenter trial in the United Kingdom, 5937 participants aged ≥ 60 years were randomly assigned to receive allopurinol or usual care and followed for the composite outcome of MI, stroke, or cardiovascular death. After an average of 5 years, those assigned to allopurinol and those assigned to usual care had similar rates of the composite endpoint (11 versus 11.3 percent; HR 1.04. 95%

CI 0.89-1.21). These results do not support the hypothesis that allopurinol be given to individuals with ischemic heart disease for secondary CVD prevention.

H. Secondary Prevention in Older Adults

- Age is a major risk factor for all clinical manifestations of CVD. As the relative benefits of both therapeutic lifestyle changes and adjunctive drug therapies appear to be similar across all ages up to approximately 85 years, the absolute benefits are larger in older adults. We offer preventive strategies to older adults with the caveat that randomized trials have enrolled and followed patients into their 80s, but there are far more patients in middle than older ages.
- In addition, for many older adults, maintaining a high quality of life may be more important than quantity of life. These issues need to be considered by the health care provider and each of their older adult patients.
- Since older adults tend to be on many drug therapies, clinicians should be aware of the greater potential for drug-drug interactions, especially in those with high-risk comorbidities such as chronic kidney disease.

I. Patient Education

- A. Patient education regarding his or her risk factors and their management is central to secondary prevention. Patients with chronic coronary syndrome, also referred to as stable ischemic heart disease, should have an individualized education plan to optimize care and promote wellness that includes education on medication adherence; an explanation of medication management and cardiovascular risk reduction strategies in a manner that respects the patient's level of understanding; a comprehensive review of all therapeutic lifestyle changes of proven benefit, a description of appropriate levels of exercise; introduction to self-monitoring skills; and information on how to recognize worsening cardiovascular symptoms and take appropriate action.

J. Summary and Recommendations

- A. Identifying patients at high risk:

1. Patients with established coronary heart disease have higher risks of subsequent cardiovascular events, including myocardial infarction, stroke, and death from cardiovascular disease.

B. Lifestyle modifications:

1. Therapeutic lifestyle changes of proven benefit include avoidance or cessation of smoking, increasing levels of daily physical activity, and a healthy diet. Modifications of multiple major risk factors may produce additive benefits.

C. Pharmacologic treatment:

1. Statins: We treat all patients with atherosclerotic cardiovascular disease (ASCVD), as well as individuals with a 10-year risk >20 percent, with evidence-based doses of a high-intensity statin regardless of the baseline low-density lipoprotein cholesterol.
2. Aspirin: Patients with established ASCVD are treated with long-term aspirin therapy.
3. Colchicine: For patients with chronic coronary disease who are receiving other secondary preventive drug therapies, we suggest adding colchicine 0.5 (or 0.6) mg per day. (**Grade 2B**)

D. Anticoagulant therapy for some patients:

1. For most patients with stable coronary artery disease on antiplatelet therapy, we do not substitute or add a full-dose oral anticoagulant therapy to aspirin. For some stable ASCVD patients who are at high risk of cardiovascular events and at low risk for bleeding, a regimen of rivaroxaban 2.5 mg orally twice per day and aspirin may be considered.

E. Other potential treatments:

1. Other medications that may be of benefit in some patients include beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or aldosterone blockers.

Annual Measurement for Effectiveness of Cardiovascular Conditions Guideline

HEDIS® Guidelines for Cardiovascular Conditions, Commercial and Medicare populations:

- ***Controlling High Blood Pressure***
- ***Persistence of Beta-Blocker Treatment After a Heart Attack***
- ***Statin Therapy for Patients With Cardiovascular Disease***
- ***Cardiac Rehabilitation***

References:

[1] [http://www.uptodate.com/contents/overview-of-the-prevention-of-cardiovascular-disease-events-in-those-with-established-disease-\(secondary-prevention\)](http://www.uptodate.com/contents/overview-of-the-prevention-of-cardiovascular-disease-events-in-those-with-established-disease-(secondary-prevention))

Topic Last updated January 2, 2025

Literature review current through August 2025

[2] NCQA; Technical Specifications for Health Plans; HEDIS MY 2026, Volume 2